News & Updates

Follow-up data from two replicate ongoing phase III trials – Measure Up 1 and Measure Up 2 – demonstrated favourable longer-term benefit-risk profile of upadacitinib in adolescents and adults with moderate-to-severe atopic dermatitis (AD).

In patients who suffer from antihistamine-resistant chronic urticaria (CU), lirentelimab seems to be effective at controlling the disease and reducing disease activity, reports a recent study.

Vitiligo patients suffer from greater levels of depression and anxiety, both of which appear to be associated with serum levels of corticotropin releasing hormone, reveals a recent study.

A topical formulation containing chitosan-coated Chamomilla recutita (L.) rauschert microparticles does not lower any grade of radiodermatitis (RD) but is effective in reducing grade ≥2 toxicity to improve skin recovery and diminish high-intensity local symptoms in women with breast cancer, a study has shown.

The combination of ipilimumab and nivolumab may provide a progression-free survival (PFS) benefit in patients with metastatic or unresectable melanoma who did not respond to anti-PD-1/anti-PD-L1 therapy, according to a small study presented at AACR 2022.

Body mass index (BMI) appears to contribute to the development of psoriasis, according to a study, which notes a graded association between BMI and risk of psoriasis.

A once-daily dose of oral baricitinib may encourage hair regrowth in patients with severe alopecia areata, according to results of the phase III BRAVE-AA studies presented at AAD 2022.